Alcon Expands Clareon Portfolio with TruPlus IOL Launch

Event summary

  • Alcon launched Clareon TruPlus, an enhanced design monofocal and toric intraocular lens (IOL), at ASCRS 2026 in Washington, D.C.
  • TruPlus offers a 3.5 letter improvement in simulated visual acuity at -1.5 diopters compared to Clareon Monofocal.
  • The new IOL leverages Opti-Balance Technology to extend depth of focus while maintaining distance image quality.
  • Alcon presented over 60 scientific studies at ASCRS, highlighting innovations across cataract, refractive, and ocular surface care.

The big picture

Alcon's launch of Clareon TruPlus underscores its strategy to dominate the cataract surgery market with incremental innovations. The enhanced monofocal IOL positions Alcon to capture surgeons seeking improved visual outcomes without the trade-offs of premium IOLs. With over 175 million IOLs implanted globally, Alcon's broad portfolio and continuous innovation reinforce its leadership in eye care.

What we're watching

Market Adoption
The pace at which Clareon TruPlus gains surgeon and patient acceptance will determine its market penetration.
Competitive Response
Whether competitors like Johnson & Johnson Vision (TECNIS Eyhance) will introduce countermeasures to maintain market share.
Regulatory Approvals
The timeline for TruPlus approvals in additional markets beyond the U.S., which will impact global revenue growth.